anmelden
SPI Healthcare
3.597,97
PKT
+5,14
PKT
+0,14
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SPI Healthcare-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 07.02.22 | Roche Overweight | Barclays Capital | |
| 04.02.22 | Roche Overweight | Barclays Capital | |
| 04.02.22 | Roche Neutral | UBS AG | |
| 03.02.22 | Novartis Neutral | UBS AG | |
| 03.02.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.02.22 | Novartis Sell | Deutsche Bank AG | |
| 03.02.22 | Novartis Neutral | Credit Suisse Group | |
| 03.02.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 03.02.22 | Roche Buy | Jefferies & Company Inc. | |
| 02.02.22 | Novartis Market-Perform | Bernstein Research | |
| 02.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.02.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.22 | Novartis Underweight | Barclays Capital | |
| 02.02.22 | Novartis Buy | Jefferies & Company Inc. | |
| 01.02.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.22 | Novartis Underweight | Barclays Capital | |
| 31.01.22 | Roche Overweight | Barclays Capital | |
| 26.01.22 | Roche Buy | Deutsche Bank AG | |
| 26.01.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 26.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 25.01.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 24.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 20.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.01.22 | Roche Buy | Deutsche Bank AG | |
| 14.01.22 | Novartis Equal-weight | Morgan Stanley | |
| 13.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 12.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 11.01.22 | Roche Buy | Deutsche Bank AG | |
| 07.01.22 | Novartis Neutral | UBS AG | |
| 04.01.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 04.01.22 | Roche Outperform | Bernstein Research | |
| 04.01.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 23.12.21 | Novartis Buy | Jefferies & Company Inc. | |
| 23.12.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 20.12.21 | Novartis Buy | Jefferies & Company Inc. | |
| 20.12.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.12.21 | Novartis Sell | Deutsche Bank AG | |
| 16.12.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.12.21 | Novartis Underweight | JP Morgan Chase & Co. |
